Total submissions: 40
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Evidence- |
RCV000112356 | SCV000244362 | benign | Breast-ovarian cancer, familial, susceptibility to, 1 | 2015-08-10 | reviewed by expert panel | curation | IARC class based on posterior probability from multifactorial likelihood analysis, thresholds for class as per Plon et al. 2008 (PMID: 18951446). Class 1 based on posterior probability = 0.00000000000309 |
Labcorp Genetics |
RCV000048591 | SCV000076604 | benign | Hereditary breast ovarian cancer syndrome | 2024-02-01 | criteria provided, single submitter | clinical testing | |
Counsyl | RCV000112356 | SCV000154028 | benign | Breast-ovarian cancer, familial, susceptibility to, 1 | 2014-03-19 | criteria provided, single submitter | literature only | |
Michigan Medical Genetics Laboratories, |
RCV000112356 | SCV000195930 | benign | Breast-ovarian cancer, familial, susceptibility to, 1 | 2014-11-03 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV000162492 | SCV000212874 | benign | Hereditary cancer-predisposing syndrome | 2014-07-21 | criteria provided, single submitter | clinical testing | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Eurofins Ntd Llc |
RCV000120258 | SCV000226128 | benign | not specified | 2014-07-10 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000048591 | SCV000494296 | benign | Hereditary breast ovarian cancer syndrome | 2014-01-24 | criteria provided, single submitter | clinical testing | |
Cancer Genetics and Genomics Laboratory, |
RCV000120258 | SCV000586900 | benign | not specified | 2017-04-18 | criteria provided, single submitter | clinical testing | |
Genetic Services Laboratory, |
RCV000120258 | SCV000593659 | benign | not specified | 2016-12-09 | criteria provided, single submitter | clinical testing | |
ARUP Laboratories, |
RCV000034752 | SCV000602672 | benign | not provided | 2023-09-25 | criteria provided, single submitter | clinical testing | |
Color Diagnostics, |
RCV000162492 | SCV000683192 | likely benign | Hereditary cancer-predisposing syndrome | 2014-11-11 | criteria provided, single submitter | clinical testing | |
Genome Diagnostics Laboratory, |
RCV000112356 | SCV000743392 | benign | Breast-ovarian cancer, familial, susceptibility to, 1 | 2014-10-09 | criteria provided, single submitter | clinical testing | |
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV000112356 | SCV000744613 | benign | Breast-ovarian cancer, familial, susceptibility to, 1 | 2015-09-21 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV000120258 | SCV000806953 | benign | not specified | 2016-11-07 | criteria provided, single submitter | clinical testing | |
Mendelics | RCV000112356 | SCV001140518 | likely benign | Breast-ovarian cancer, familial, susceptibility to, 1 | 2019-05-28 | criteria provided, single submitter | clinical testing | |
Illumina Laboratory Services, |
RCV000112356 | SCV001280758 | benign | Breast-ovarian cancer, familial, susceptibility to, 1 | 2018-08-07 | criteria provided, single submitter | clinical testing | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. The evidence from the literature, in combination with allele frequency data from public databases where available, was sufficient to rule this variant out of causing disease. Therefore, this variant is classified as benign. |
Quest Diagnostics Nichols Institute San Juan Capistrano | RCV000120258 | SCV001469392 | benign | not specified | 2020-06-15 | criteria provided, single submitter | clinical testing | |
National Health Laboratory Service, |
RCV000048591 | SCV002025932 | benign | Hereditary breast ovarian cancer syndrome | 2022-04-19 | criteria provided, single submitter | clinical testing | |
Ce |
RCV000034752 | SCV002498278 | likely benign | not provided | 2024-08-01 | criteria provided, single submitter | clinical testing | BRCA1: BS2 |
Genetics Program, |
RCV000048591 | SCV002515214 | likely benign | Hereditary breast ovarian cancer syndrome | 2021-11-01 | criteria provided, single submitter | research | |
Sema4, |
RCV000162492 | SCV002537758 | benign | Hereditary cancer-predisposing syndrome | 2020-05-20 | criteria provided, single submitter | curation | |
Center for Genomic Medicine, |
RCV000120258 | SCV002550974 | benign | not specified | 2023-08-15 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002490467 | SCV002803547 | benign | Familial cancer of breast; Breast-ovarian cancer, familial, susceptibility to, 1; Pancreatic cancer, susceptibility to, 4; Fanconi anemia, complementation group S | 2021-12-23 | criteria provided, single submitter | clinical testing | |
KCCC/NGS Laboratory, |
RCV000112356 | SCV004016787 | benign | Breast-ovarian cancer, familial, susceptibility to, 1 | 2023-07-07 | criteria provided, single submitter | clinical testing | |
All of Us Research Program, |
RCV000112356 | SCV004817658 | likely benign | Breast-ovarian cancer, familial, susceptibility to, 1 | 2024-02-05 | criteria provided, single submitter | clinical testing | |
Breakthrough Genomics, |
RCV000034752 | SCV005251036 | benign | not provided | criteria provided, single submitter | not provided | ||
Biesecker Lab/Clinical Genomics Section, |
RCV000034752 | SCV000043157 | no known pathogenicity | not provided | 2012-07-13 | no assertion criteria provided | research | Converted during submission to Benign. |
ITMI | RCV000120258 | SCV000084410 | not provided | not specified | 2013-09-19 | no assertion provided | reference population | |
Breast Cancer Information Core |
RCV000112356 | SCV000145117 | benign | Breast-ovarian cancer, familial, susceptibility to, 1 | 1999-06-21 | no assertion criteria provided | clinical testing | |
Pathway Genomics | RCV000112356 | SCV000187728 | likely benign | Breast-ovarian cancer, familial, susceptibility to, 1 | 2014-07-24 | no assertion criteria provided | literature only | |
Sharing Clinical Reports Project |
RCV000112356 | SCV000189343 | benign | Breast-ovarian cancer, familial, susceptibility to, 1 | 2011-03-08 | no assertion criteria provided | clinical testing | |
Research Molecular Genetics Laboratory, |
RCV000120258 | SCV000587407 | benign | not specified | 2014-01-31 | no assertion criteria provided | research | |
Department of Pathology and Laboratory Medicine, |
RCV000120258 | SCV000591526 | benign | not specified | no assertion criteria provided | clinical testing | The BRCA1, c.4535G>T, p.Ser1512Ile variant has been reported in the literature in 6/2156 proband chromosomes of individuals with HBOC and sporadic breast/ ovarian cancer. It was also identified in 6/1360 of the control chromosomes evaluated (Al-Mulla_2008, Bergthorsson_2001, Young_2009, Wagner_1998, Tavtigian_2006, Phelan_2005, Sanz_2010). The variant has also been previously identified in our laboratory in 6 individuals, and was classified as benign. The variant is reported in the BIC (x58), Exome Server and BOCs databases. It is also listed in the dbSNP database as coming from a "clinical source" (ID#: rs1800744) with a MAF score of 0.001 (1000 Genomes), increasing the likelihood that this is a low frequency benign variant. The residue is not conserved in mammals, and computational analyses (PolyPhen, SIFT, AlignGVGD) provide inconsistent predictions regarding the impact to the protein. However, this information is not very predictive of pathogenicity. Functional studies examining the effect of the variant on transcriptional activation found that the variant levels were equal to or higher than that of wild type BRCA1, suggesting that it does not represent a high risk variant & is likely to have low clinical significance (Phelan_2005). Studies have also reported that p.Ser1512Ile has been found to co-occur with other known BRCA1 pathogenic variants numerous times, increasing the likelihood that this variant does not have clinical significance (Bergthorsson_2001, Tavtigian_2006, Phelan_2005). In summary, based on the above information, this variant is classified as Benign. | |
Diagnostic Laboratory, |
RCV000112356 | SCV000733609 | benign | Breast-ovarian cancer, familial, susceptibility to, 1 | no assertion criteria provided | clinical testing | ||
Mayo Clinic Laboratories, |
RCV000034752 | SCV000778738 | benign | not provided | 2016-12-06 | no assertion criteria provided | clinical testing | |
True Health Diagnostics | RCV000162492 | SCV000805231 | likely benign | Hereditary cancer-predisposing syndrome | 2018-04-25 | no assertion criteria provided | clinical testing | |
Clinical Genetics Laboratory, |
RCV000120258 | SCV001906427 | benign | not specified | no assertion criteria provided | clinical testing | ||
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, |
RCV000120258 | SCV001953385 | benign | not specified | no assertion criteria provided | clinical testing | ||
Institute for Biomarker Research, |
RCV000048591 | SCV001977041 | benign | Hereditary breast ovarian cancer syndrome | 2021-09-27 | no assertion criteria provided | clinical testing | |
Laboratory of Diagnostic Genome Analysis, |
RCV000120258 | SCV002035335 | benign | not specified | no assertion criteria provided | clinical testing |